Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FF-10850 in Advanced Solid Tumors
NCT04047251Phase 1Active, not recruiting
- Sponsor
- Fujifilm Pharmaceuticals
- Start
- Nov 2019
- Primary completion
- Dec 2026
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 1
01
Overview
Phase 1, open-label trial of topotecan liposome in solid tumor, ovarian cancer and Merkel cell carcinoma (MCC) (5 cohorts), sponsored by Fujifilm Pharmaceuticals. Primary endpoints: Treatment Emergent Adverse Events at 4 years, Dose-Limiting Toxicities at 4 years and 2 more. Started Nov 2019; status: active, not recruiting.
02
Drugs
topotecan liposome
03
Conditions
solid tumorovarian cancerMerkel cell carcinoma (MCC)
Beyond the preview
Go deeper on NCT04047251.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04047251.